- Tonix Pharmaceuticals (TNXP +5.7%) says it expects to report results from Phase IIb testing of its TNX-102 SL drug candidate in patients with fibromyalgia during H2 2014.
- TNXP says it began enrollment in the BESTFIT trial last September which was expected to monitor ~120 patients split equally between groups receiving either TNX-102 SL or placebo, measuring changes in pain intensity.
- TNXP also says it expects to begin a trial of TNX-102 SL as a potential treatment for post-traumatic stress disorder and tension-type headache during Q3 and Q4, respectively.
Tonix Pharma expects results on fibromyalgia test during H2, shares +5.7%
Feb 4 2014, 15:10 ET